Skip to main content
Equibles
ABT logo

ABT · Abbott Laboratories

Track ABT — free

Use ABT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$108.52 +1.27 (+1.18%) At close · Nov 13
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$187.95B
Shares
1.73B
Volume · Nov 13 6.2M Avg daily vol (3M) 8.95M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$108.52 Open$108.20 Day$107.03–109.28 52W close$82.56–130.59 Avg vol 30d9.6M Short int19.1M · 1.1% of shares · 1.9d Short vol26% Last earningsOct 21, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Next earnings call
Jan 21, 2027 Est · unconfirmed · in 10 wks
Q3 2026 earnings call transcript
call held Oct 21, 2026
Play latest call

Latest documents

2026
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Abbott plans Nutrition separation by end of 2027

Abbott Laboratories plans to separate its Nutrition business as an independent, publicly traded company by the end of 2027. Third-quarter net sales rose 14.8% excluding foreign exchange, aided by its March 23, 2026 acquisition of Exact Sciences for approximately $20.6 billion.

Revenue $13.01B ▲ 14.5% Net income $920M ▼ 44.0% Diluted EPS $0.53 ▼ 43.6%
Read from the MD&A section
5 source passages
In October 2026, Abbott announced its intention to separate its Nutrition business into an independent, publicly traded company. Abbott expects to complete the transaction by the end of 2027, subject to customary conditions, including regulatory approvals, the effectiveness of a registration statement on Form 10, and final approval by the Abbott board of directors. The 14.8 percent increase in total net sales during the third quarter of 2026, excluding the impact of foreign exchange, was driven by the acquisition of Exact Sciences Corporation (Exact Sciences) and high single-digit growth in Medical Devices and Established Pharmaceutical Products. The Exact Sciences acquisition was completed on March 23, 2026, and its results are reported within the Diagnostic Products segment as Cancer Diagnostics from the date of acquisition. On March 23, 2026, Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion. Open the document at this passage
Oct 21
Earnings call
Q3 2026 earnings call

Abbott plans to spin off nutrition as a publicly traded company by the end of next year. Third-quarter sales rose 7%, adjusted earnings per share was $1.42, and fourth-quarter adjusted earnings per share is forecast at $1.62 to $1.67.

Read from the first part of this long document
Oct 21
Current report 8-K
Other events

Abbott Laboratories plans to separate its Nutrition business into an independent company via a tax-free distribution by the end of 2027. The new company would have approximately $8.5 billion in annual sales, while Abbott would have approximately $42 billion.

Oct 21
Current report 8-K
Financial results

Abbott reported results for the third quarter ended Sept. 30, 2026: sales increased 14.5 percent, comparable sales growth was 7.0 percent, and adjusted diluted EPS was $1.42. Full-year adjusted diluted EPS guidance was $5.50 to $5.55.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$48.23B
Trailing 12 months
Net income (TTM)
$4.70B
Trailing 12 months
Revenue growth YoY
+14.5%
Year over year
Operating margin
13.8%
Trailing 12 months
P / E (TTM)
40.5
Trailing earnings · reciprocal yield 2.5%
FCF yield
3.6%
TTM · current market cap
Return on invested capital
6.1%
Trailing 12 months
Net cash
−$26.86B
Latest balance sheet
Dividend yield
2.3%
Trailing 12 months
Shares change YoY
-0.7%
Year over year · fewer shares
Price change (1Y)
-16.0%
Trailing year
Short interest
1.1%
Latest settlement · 1.9 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲7.2% $10.97B $9.23B '24 Q4* ▲4% $10.36B $1.32B '25 Q1 ▲7.4% $11.14B $1.78B '25 Q2 ▲6.9% $11.37B $1.64B '25 Q3 ▲4.4% $11.46B $1.78B '25 Q4* ▲7.8% $11.16B $1.08B '26 Q1 ▲13% $12.59B $928.00M '26 Q2 LATEST ▲14.5% $13.01B $920.00M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Mentioned in fund letters

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +7%
above
Price vs 50-day avg +4%
above
RSI (14) 54
neutral
MACD trend Negative
52-week position 54%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Strong
1-month return +3%
trailing
6-month return +25%
trailing
YTD return −13%
this year
Relative strength +25%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $104 › 200d $102 — 50d above 200d
Institutional flow Accumulating
2,766 of 3,004 funds reported for Sep 30 · net +38.2M sh shares · +171 new
Insider flow Distributing
Net -$46.6M over 90 days · 100% sells
Short interest Rising
1.10% of shares out · ▲ +9.6% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
3,004 holders — mid 3-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Fair
Revenue growth +6%
Y/Y
EPS growth −51%
Y/Y
Free cash flow $7.4B
Valuation P/E 40.5
rich
Buyback $6.7B
remaining
Balance sheet $4.4B
net debt
Quant / Vol
risk profile
Moderate
Volatility 28%
annualized · 1-yr
Max drawdown −37%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 7
Latest guidance · from the 8-K filed Oct 21, 2026
full-year 2026
Adjusted diluted earnings per share Non-GAAP $5.50 – $5.55
fourth-quarter 2026
Adjusted diluted earnings per share Non-GAAP $1.62 – $1.67
Previous outlook earlier release · from the Earnings Call filed Jul 16, 2026

Still-open targets the latest release did not restate under the same label.

EPS guidance · full year $5.45 – $5.60
Exchange impact on sales · full year 1%
Nutrition growth · going forward 2% – 4%
Diagnostics growth · going forward 7% – 8%
EPD growth · going forward 7% – 9%
MedTech growth · going forward 8% – 10%
Total company growth · going forward 6.5% – 8.5%
Prior guidance period ended · from the 8-K filed Jan 22, 2026
Adjusted diluted earnings per share · first-quarter 2026 $1.12 – $1.18
Guided vs delivered · last 7 settled
Diluted earnings per share under GAAP third-quarter 2024
guided $0.85 – $0.89
$0.94 Beat +8.0%
Diluted earnings per share under GAAP full-year 2024
guided $3.25 – $3.40
$7.64 Beat +129.8%
Diluted earnings per share under GAAP second-quarter 2024
guided $0.69 – $0.73
$0.74 Beat +4.2%
Diluted earnings per share from continuing operations under GAAP full-year 2023
guided $3.05 – $3.25
$3.26 Beat +3.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+7% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
54 Neutral
MACD trend
Negative Bearish
52-week position
54% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $104 › 200d $102 — 50d above 200d
Institutional flow Accumulating
2,766 of 3,004 funds reported for Sep 30 · net +38.2M sh shares · +171 new
Insider flow Distributing
Net -$46.6M over 90 days · 100% sells
Short interest Rising
1.10% of shares out · ▲ +9.6% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
3,004 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $83 Now $109 · 54% Range high $131
vs 200-day avg +7% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABT
Abbott Laboratories
this stock
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
 $131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
 $117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
 $64.27B -53.5% +12.5% 18.8 2.4%
EW
Edwards Lifesciences Corp
 $61.61B +25.7% +11.5% 60.5 1.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
3,096
% held
83.2%
Reported
2,766 of 3,004
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,084
View
Short & Settlement
Short Interest Rising
Shares short
19.1M
Days to cover
1.9d
Change
+1.7M sh
View
Short Volume
Short vol %
26%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
15
Value
$1.5K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
50.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$46.6M
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Sell
Member
Pete Sessions
Amount
$50.0K–$100.0K
Traded
Oct 2, 2026
View
Financials
Financials
Revenue (FY)
$44.3B
Net income (FY)
$6.5B
EPS diluted
$3.72
View
Buybacks
Authorized
$7.0B
Remaining
$6.7B
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 4, 2026
This year
20

Abbott Laboratories plans to separate its Nutrition business as an independent, publicly traded company by the end of 2027. Third-quarter net sales rose 14.8% excluding foreign exchange, aided by its March 23, 2026 acquisition of Exact Sciences for approximately $20.6 billion.

View
Proposed Sales
Value
$406.0K
Shares
3.5K
Filed
Nov 5, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 21, 2026
View
Investor Relations
Latest news
Abbott announces its intention to…
Published
Oct 21, 2026
View

Performance

5D 20D 120D MTD YTD
ABT -1.3% +3.5% +25.2% +2.2% -13.4%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -3.9% +4.6% +24.7% +2.4% -24.0%

Capital returns

Latest dividend
$0.63 / share · ex Oct 15, 2026
Raised 6.8%
Paid (TTM)
$2.52 / share · 4 payouts
Dividend yield (TTM, derived)
2.32%
Full dividend history
Buyback program · as of Mar 31, 2026
Authorized
$7.00B
Spent (derived)
$300.00M
Remaining
$6.70B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1800 CUSIP 002824100 13F (30d) 2389 filings 2259 filers Visit website Investor relations